| Roy Slootheer, APRN | |
|
1308 River Birch Run, Moore, OK 73160-1378 | |
| (405) 201-1333 | |
| Not Available |
| Full Name | Roy Slootheer |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 8 Years |
| Location | 1308 River Birch Run, Moore, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356892921 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | R0116739 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Norman Regional | Norman, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Premier Healthcare, Aprn-cnp, Pc | 7315362266 | 2 |
News Archive
Kaiser Health News staff writer Jessica Marcy reports: "Many parents breathed a sigh of relief when they heard that health insurance companies were opening up coverage to young adult children.
LaVison BioTec, developers of advanced microscopy solutions for the life sciences, report on users of their Ultramicroscope Light Sheet Fluorescence Microscope system to aid the research of the Miami Project to Cure Paralysis under the supervision of Professor Vance Lemmon, the Walter G. Ross Distinguished Chair in Developmental Neuroscience & Professor of Neurological Surgery at the University of Miami.
Drug company Celgene says it has halted a pivotal-stage trial of its Thalomid drug earlier than expected after the drug was shown to dramatically limit the progress of the blood cancer multiple myeloma.
Researchers from the University of Cambridge and the Massachusetts Institute of Technology have made a breakthrough by using supercritical carbon dioxide (scCO2) as a reaction medium for the preparation of molecules of interest to the pharmaceutical industry.
Watson Pharmaceuticals, Inc. and Natco Pharma Limited today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lenalidomide 5, 10, 15 and 25 mg product. Natco's lenalidomide tablets are generic versions of Celgene's Revlimid ® Tablets.
› Verified 7 days ago
| Entity Name | Board Of Regents Of The University Of Oklahoma - Ou Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801869250 PECOS PAC ID: 2860304334 Enrollment ID: O20031103000607 |
News Archive
Kaiser Health News staff writer Jessica Marcy reports: "Many parents breathed a sigh of relief when they heard that health insurance companies were opening up coverage to young adult children.
LaVison BioTec, developers of advanced microscopy solutions for the life sciences, report on users of their Ultramicroscope Light Sheet Fluorescence Microscope system to aid the research of the Miami Project to Cure Paralysis under the supervision of Professor Vance Lemmon, the Walter G. Ross Distinguished Chair in Developmental Neuroscience & Professor of Neurological Surgery at the University of Miami.
Drug company Celgene says it has halted a pivotal-stage trial of its Thalomid drug earlier than expected after the drug was shown to dramatically limit the progress of the blood cancer multiple myeloma.
Researchers from the University of Cambridge and the Massachusetts Institute of Technology have made a breakthrough by using supercritical carbon dioxide (scCO2) as a reaction medium for the preparation of molecules of interest to the pharmaceutical industry.
Watson Pharmaceuticals, Inc. and Natco Pharma Limited today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lenalidomide 5, 10, 15 and 25 mg product. Natco's lenalidomide tablets are generic versions of Celgene's Revlimid ® Tablets.
› Verified 7 days ago
| Entity Name | Advance Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750395448 PECOS PAC ID: 0244122083 Enrollment ID: O20040326000898 |
News Archive
Kaiser Health News staff writer Jessica Marcy reports: "Many parents breathed a sigh of relief when they heard that health insurance companies were opening up coverage to young adult children.
LaVison BioTec, developers of advanced microscopy solutions for the life sciences, report on users of their Ultramicroscope Light Sheet Fluorescence Microscope system to aid the research of the Miami Project to Cure Paralysis under the supervision of Professor Vance Lemmon, the Walter G. Ross Distinguished Chair in Developmental Neuroscience & Professor of Neurological Surgery at the University of Miami.
Drug company Celgene says it has halted a pivotal-stage trial of its Thalomid drug earlier than expected after the drug was shown to dramatically limit the progress of the blood cancer multiple myeloma.
Researchers from the University of Cambridge and the Massachusetts Institute of Technology have made a breakthrough by using supercritical carbon dioxide (scCO2) as a reaction medium for the preparation of molecules of interest to the pharmaceutical industry.
Watson Pharmaceuticals, Inc. and Natco Pharma Limited today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lenalidomide 5, 10, 15 and 25 mg product. Natco's lenalidomide tablets are generic versions of Celgene's Revlimid ® Tablets.
› Verified 7 days ago
| Entity Name | Immediate Care Of Oklahoma Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164697694 PECOS PAC ID: 2668540774 Enrollment ID: O20081002000355 |
News Archive
Kaiser Health News staff writer Jessica Marcy reports: "Many parents breathed a sigh of relief when they heard that health insurance companies were opening up coverage to young adult children.
LaVison BioTec, developers of advanced microscopy solutions for the life sciences, report on users of their Ultramicroscope Light Sheet Fluorescence Microscope system to aid the research of the Miami Project to Cure Paralysis under the supervision of Professor Vance Lemmon, the Walter G. Ross Distinguished Chair in Developmental Neuroscience & Professor of Neurological Surgery at the University of Miami.
Drug company Celgene says it has halted a pivotal-stage trial of its Thalomid drug earlier than expected after the drug was shown to dramatically limit the progress of the blood cancer multiple myeloma.
Researchers from the University of Cambridge and the Massachusetts Institute of Technology have made a breakthrough by using supercritical carbon dioxide (scCO2) as a reaction medium for the preparation of molecules of interest to the pharmaceutical industry.
Watson Pharmaceuticals, Inc. and Natco Pharma Limited today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lenalidomide 5, 10, 15 and 25 mg product. Natco's lenalidomide tablets are generic versions of Celgene's Revlimid ® Tablets.
› Verified 7 days ago
| Entity Name | Premier Healthcare, Aprn-cnp, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144847542 PECOS PAC ID: 7315362266 Enrollment ID: O20200810000969 |
News Archive
Kaiser Health News staff writer Jessica Marcy reports: "Many parents breathed a sigh of relief when they heard that health insurance companies were opening up coverage to young adult children.
LaVison BioTec, developers of advanced microscopy solutions for the life sciences, report on users of their Ultramicroscope Light Sheet Fluorescence Microscope system to aid the research of the Miami Project to Cure Paralysis under the supervision of Professor Vance Lemmon, the Walter G. Ross Distinguished Chair in Developmental Neuroscience & Professor of Neurological Surgery at the University of Miami.
Drug company Celgene says it has halted a pivotal-stage trial of its Thalomid drug earlier than expected after the drug was shown to dramatically limit the progress of the blood cancer multiple myeloma.
Researchers from the University of Cambridge and the Massachusetts Institute of Technology have made a breakthrough by using supercritical carbon dioxide (scCO2) as a reaction medium for the preparation of molecules of interest to the pharmaceutical industry.
Watson Pharmaceuticals, Inc. and Natco Pharma Limited today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lenalidomide 5, 10, 15 and 25 mg product. Natco's lenalidomide tablets are generic versions of Celgene's Revlimid ® Tablets.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Roy Slootheer, APRN 1308 River Birch Run, Moore, OK 73160-1378 Ph: (405) 201-1333 | Roy Slootheer, APRN 1308 River Birch Run, Moore, OK 73160-1378 Ph: (405) 201-1333 |
News Archive
Kaiser Health News staff writer Jessica Marcy reports: "Many parents breathed a sigh of relief when they heard that health insurance companies were opening up coverage to young adult children.
LaVison BioTec, developers of advanced microscopy solutions for the life sciences, report on users of their Ultramicroscope Light Sheet Fluorescence Microscope system to aid the research of the Miami Project to Cure Paralysis under the supervision of Professor Vance Lemmon, the Walter G. Ross Distinguished Chair in Developmental Neuroscience & Professor of Neurological Surgery at the University of Miami.
Drug company Celgene says it has halted a pivotal-stage trial of its Thalomid drug earlier than expected after the drug was shown to dramatically limit the progress of the blood cancer multiple myeloma.
Researchers from the University of Cambridge and the Massachusetts Institute of Technology have made a breakthrough by using supercritical carbon dioxide (scCO2) as a reaction medium for the preparation of molecules of interest to the pharmaceutical industry.
Watson Pharmaceuticals, Inc. and Natco Pharma Limited today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lenalidomide 5, 10, 15 and 25 mg product. Natco's lenalidomide tablets are generic versions of Celgene's Revlimid ® Tablets.
› Verified 7 days ago
Mrs. Kristen Lanae Rosenau, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2900 S Telephone Rd Ste 250, Moore, OK 73160 Phone: 405-237-7512 | |
Haley Harrison Strutton, DNP, APRN, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 400 N Eastern Ave, Moore, OK 73160 Phone: 405-757-7818 | |
Mr. Christopher R Stepp, MSN, FNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 612 Madeline Ln, Moore, OK 73160 Phone: 580-334-8661 | |
Dr. Jeffery David Barlow, DNP, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 601 S Service Rd # 6253, Moore, OK 73160 Phone: 888-611-4429 Fax: 888-611-4429 | |
My Nguyen, APRN CNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 400 N Eastern Ave, Moore, OK 73160 Phone: 405-757-7818 Fax: 405-703-3116 | |
Caroline Anne Whitaker, PMHNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1105 Sw 30th Ct, Moore, OK 73160 Phone: 405-378-4439 | |
Miss Jennifer Ann Barber, APRN, ATC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2900 S Telephone Rd, Moore, OK 73160 Phone: 405-488-0750 Fax: 405-237-7512 |